In the heart of Switzerland's capital
CSL Behring AG in Bern specializes in the manufacture of medications for treating immune deficiency disorders and disorders of the immune function, as well as medications for rhesus prophylaxis and albumin solutions for shock and burn victims.
The production plants of CSL Behring AG are licensed by the Swiss health authorities and the American FDA. Every year, around five million liters of human plasma are used to isolate and manufacture important proteins for treatments in accordance with the strictest safety and quality standards. CSL Behring AG’s products are sold around the world.
Protinus: 250m Swiss francs, 50 new jobs for Bern
On an adjacent plot of land, for which CSL Behring signed a pre-contract a few years ago, a new building is erected that will accommodate two additional manufacturing lines for immunoglobulin products. This extension of the existing Logistics and Service Center (GBZ) at Wankdorfstrasse 8 is a multi-storey building with three basement levels. Its core includes:
- immunoglobulin bulk manufacturing
- space for future sterile filling line
- utility and logistics rooms
In addition, a building envelope will be built for GBZ. This alteration (building envelope) includes the following:
- new roof and facade
- new office workspace and meeting rooms (Eastern and Southern sides)
Because of the new building envelope, the delivery of goods to Wankdorfstrasse 8 will be very low-noise. Despite the capacity expansion, lorry traffic will not increase after the completion of the project. Due to higher occupancy rates, logistics will be optimised and thus be more efficient.
CSL Behring invests 250m Swiss francs in this project and creates approximately 50 new jobs in the city of Bern.